NCT05889273 - ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

December 31, 2027

Conditions

Autism Spectrum Disorder

Interventions

DRUG

ML-004 (IR)/(ER) tablet

Participants will receive ML-004 once daily.

Trial Locations (17)

2050

Brain and Mind Centre, Camperdown

3052

The Royal Children's Hospital, Murdoch Children's Research Institute, Parkville

10314

Richmond Behavioral Associates, Staten Island

10962

Nathan Kline Institute for Psychiatric Research, Orangeburg

19063

Suburban Research Associates, Media

20010

The Children's Research Institute, Washington D.C.

32803

APG Research, LLC, Orlando

33613

University of South Florida Psychiatry and Behavioral Neurosciences, Tampa

36303

Harmonex Neuroscience Research, Dothan

48302

Neurobehavioral Medicine Group, Bloomfield Hills

65211

University of Missouri, Thompson Center for Autism & Neurodevelopment, Columbia

77381

Family Psychiatry of The Woodlands, The Woodlands

78249

Road Runner Research, Ltd., San Antonio

85006

Southwest Autism Research and Resource Center, Phoenix

91203

Cortica Healthcare, Glendale

92868

NRC Research Institute, Orange

M4G 1R8

Holland Bloorview Kids Rehabilitation Hospital, Toronto